Steve Shoptaw, Ph.D.
Co-Director, Combination Prevention Core
Co-Director, Administrative Core
|Address||David Geffen School of Medicine at UCLA
Department of Family Medicine
10880 Wilshire Boulevard, Suite 1800
Los Angeles, CA 90095-7087
|Phone||310.794.0619 ext. 225|
Steven Shoptaw, PhD is a licensed psychologist and Executive Director of the Center for Behavioral and Addiction Medicine (CBAM) at UCLA. He is also a Professor in the UCLA Departments of Family Medicine and Psychiatry and Biobehavioral Sciences and is Vice Chair of Research in Family Medicine. Dr. Shoptaw has a portfolio of work that focuses on the treatment of addiction and HIV prevention in the context of addiction in the Western U.S., where stimulant use is the single strongest predictor of HIV transmission. For over 20 years, Dr. Shoptaw has conducted a series of clinical studies in community clinic settings, primarily on topics that involve the development of medical and behavioral interventions to treat substance abusers. Dr. Shoptaw recently completed a Phase I interaction safety study of ibudilast at relevant doses of methamphetamine and is Co-Investigator on a Phase II randomized controlled trial of ibudilast as an outpatient treatment for methamphetamine dependence. Dr. Shoptaw is a member of the DAIDS-funded, HIV Prevention Trials Network (HPTN) Executive Committee, and site Principal Investigator for HPTN-073, a feasibility study of Pre-Exposure Prophylaxis (Truvada) in Black men who have sex with men. Additionally, Dr. Shoptaw is a Co-PI on a 5-year NIDA-funded cooperative agreement (U01 DA036267) to establish a cohort of minority men who have sex with men to investigate interactions between non-injection use of methamphetamine, cocaine, opiates and binge drinking and transmission and progression of HIV (“The m-Study). As the Director for the Combination Prevention Core for the UCLA Center for HIV Identification Prevention and Treatment Services, Dr. Shoptaw works with a team of colleagues to develop funded research on application of the next generation of technological advances (e.g., using cell phones, Internet) and biomedical approaches (microbicides, stem cells) to preventing HIV transmission. He is also Director of a T32 Training Program on Addiction Medicine in Primary Care funded by the National Institute on Drug Abuse. Dr. Shoptaw eagerly seeks out opportunities to mentor new investigators interested in academic careers along these topics and has mentored more than twenty pre- and post-doctoral students.
Ph.D., Psychology, University of California, Los Angeles, California, US
M.A., Psychology, University of California, Los Angeles, California, US
B.A., Psychology, University of California, Los Angeles, California, US
Research and Interests:
Addiction medicine research, medication development for methamphetamine abuse, HIV behavioral and biomedical interventionsShoptaw CV (319)